Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$44.10
-1.0%
$34.25
$13.88
$48.61
$4.14B1.132.61 million shs3.04 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-1.01%+3.38%+4.68%+58.52%+109.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$44.10
-1.0%
$34.25
$13.88
$48.61
$4.14B1.132.61 million shs3.04 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-1.01%+3.38%+4.68%+58.52%+109.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.69
Moderate Buy$47.838.47% Upside

Current Analyst Ratings Breakdown

Latest TVTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
DowngradeSell (D-)Sell (E+)
5/6/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetOverweight$40.00 ➝ $50.00
5/5/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetOutperform$53.00 ➝ $55.00
5/5/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetBuy$53.00 ➝ $59.00
5/5/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetBuy$47.00 ➝ $57.00
5/5/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetBuy$45.00 ➝ $60.00
4/24/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetBuy$54.00 ➝ $56.00
4/14/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetBuy$48.00 ➝ $53.00
4/14/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
UpgradeNeutralOverweight$49.00
4/14/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Boost Price TargetBuy$47.00 ➝ $56.00
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$490.73M8.36$0.36 per share123.02$1.06 per share41.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$25.55M-$0.23N/A28.45N/A-4.00%-26.16%-3.71%N/A

Latest TVTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/4/2026Q1 2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.2420$0.05+$0.2920-$0.40$136.23 million$127.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
3.16
3.13
3.08

Institutional Ownership

CompanyInstitutional Ownership
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46092.99 million88.86 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$44.10 -0.45 (-1.01%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$43.28 -0.82 (-1.86%)
As of 08:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.